EP Patent

EP1201242A3 — Use of mometasone furoate in an adjuvant therapy

Assigned to Merck Sharp and Dohme LLC · Expires 2003-12-03 · 22y expired

What this patent protects

Mometasome furoate is used in manufacture of a medicament for the treatment of a disease ofthe lower and/or upper airway passages and/or lungs in an adjuvant therapy, for example, with a bronchodilator.

USPTO Abstract

Mometasome furoate is used in manufacture of a medicament for the treatment of a disease ofthe lower and/or upper airway passages and/or lungs in an adjuvant therapy, for example, with a bronchodilator.

Drugs covered by this patent

Patent Metadata

Patent number
EP1201242A3
Jurisdiction
EP
Classification
—
Expires
2003-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.